MIRM insider buying and SEC filings, explained
Mirum Pharmaceuticals, Inc. · CIK 1759425
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$9.0M
Insiders who bought
1
Sold (not marked 10b5-1)
$12.4M
Planned sales (10b5-1)
$25.8M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 14, 2026 | Sale | Eric Bjerkholt (CFO) sold 9,943 shares at $98.37 ($978K). Holdings down 18% to 44,745 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 15, 2026 |
| Sep 2, 2026 | Planned (10b5-1) | Jolanda Howe (SVP, Global Controller) sold 658 shares at $100.00 ($66K), marked as a 10b5-1 plan trade. Holdings down 52% to 616 shares. | SEC filing Filed Sep 3, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Christopher Peetz (CEO and Director) sold 30,000 shares at about $98.68 ($3.0M), marked as a 10b5-1 plan trade. Holdings down 13% to 194,440 shares. | SEC filing Filed Sep 3, 2026 |
| Aug 11, 2026 | Planned (10b5-1) | Eric Bjerkholt (CFO) sold 6,001 shares at about $99.90 ($599K), marked as a 10b5-1 plan trade. Holdings down 14% to 36,355 shares. | SEC filing Filed Aug 12, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Christopher Peetz (CEO and Director) sold 20,000 shares at about $98.92 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 9% to 194,309 shares. | SEC filing Filed Aug 11, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Jolanda Howe (SVP, Global Controller) sold 1,840 shares at $105.29 ($194K), marked as a 10b5-1 plan trade. Holdings down 59% to 1,274 shares. | SEC filing Filed Aug 5, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Christopher Peetz (CEO and Director) sold 20,000 shares at about $122.27 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 9% to 194,309 shares. | SEC filing Filed Jul 8, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Eric Bjerkholt (CFO) sold 5,000 shares at about $122.25 ($611K), marked as a 10b5-1 plan trade. Holdings down 11% to 42,181 shares. | SEC filing Filed Jul 8, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Jolanda Howe (SVP, Global Controller) sold 2,721 shares at $120.00 ($327K), marked as a 10b5-1 plan trade. Holdings down 47% to 3,114 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Jolanda Howe (SVP, Global Controller) sold 2,594 shares at $101.95 ($264K), marked as a 10b5-1 plan trade. Holdings down 31% to 5,835 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 8, 2026 | Planned (10b5-1) | Eric Bjerkholt (CFO) sold 5,000 shares at about $93.82 ($469K), marked as a 10b5-1 plan trade. Holdings down 10% to 44,788 shares. | SEC filing Filed Jun 9, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Christopher Peetz (CEO and Director) sold 30,000 shares at about $95.84 ($2.9M), marked as a 10b5-1 plan trade. Holdings down 13% to 194,309 shares. | SEC filing Filed Jun 2, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Saira Ramasastry (Director) sold 3,977 shares at $100.00 ($398K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jun 2, 2026 |
| May 15, 2026 | Planned (10b5-1) | Saira Ramasastry (Director) sold 2,000 shares at $109.47 ($219K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed May 18, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Saira Ramasastry (Director) sold 2,000 shares at $96.90 ($194K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 16, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Saira Ramasastry (Director) sold 2,000 shares at $90.76 ($182K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Jolanda Howe (SVP, Global Controller) sold 4,732 shares at $91.98 ($435K). Holdings down 36% to 8,429 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Joanne Quan (Chief Medical Officer) sold 7,287 shares at $91.98 ($670K). Holdings down 28% to 18,864 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Peter Radovich (President / COO) sold 16,515 shares at $91.98 ($1.5M). Holdings down 29% to 40,272 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Christopher Peetz (CEO and Director) sold 40,985 shares at $91.98 ($3.8M). Holdings down 17% to 194,309 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Eric Bjerkholt (CFO) sold 7,287 shares at $91.98 ($670K). Holdings down 13% to 49,788 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Feb 13, 2026 | Planned (10b5-1) | Saira Ramasastry (Director) sold 2,000 shares at $102.09 ($204K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 2, 2026 | Sale | Peter Radovich (President / COO) sold 2,631 shares at $103.30 ($272K). Holdings down 11% to 20,655 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 3, 2026 |
| Feb 2, 2026 | Sale | Christopher Peetz (CEO and Director) sold 9,108 shares at $103.30 ($941K). Holdings down 5% to 160,294 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 3, 2026 |
| Feb 2, 2026 | Sale | Jolanda Howe (SVP, Global Controller) sold 968 shares at $103.30 ($100K). Holdings down 18% to 4,503 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 3, 2026 |
| Jan 26, 2026 | Sale | Jolanda Howe (SVP, Global Controller) sold 842 shares at $96.19 ($81K). Holdings down 19% to 3,700 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 26, 2026 | Sale | Peter Radovich (President / COO) sold 3,143 shares at $96.19 ($302K). Holdings down 12% to 23,286 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 26, 2026 | Sale | Christopher Peetz (CEO and Director) sold 6,831 shares at $96.19 ($657K). Holdings down 4% to 169,402 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 23, 2026 | Purchase (code P) | Patrick J Heron (Director) bought 131,425 shares indirectly (by entity) at $68.48 ($9.0M), reported as a purchase (code P). Holdings by entity up 40% to 459,010 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 26, 2026 | Sale | Eric Bjerkholt (CFO) sold 1,053 shares at $96.19 ($101K). Holdings down 2% to 43,741 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 22, 2026 | Sale | Jolanda Howe (SVP, Global Controller) sold 926 shares at $93.33 ($86K). Holdings down 23% to 3,042 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Joanne Quan (Chief Medical Officer) sold 1,822 shares at $93.33 ($170K). Holdings down 12% to 12,817 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Peter Radovich (President / COO) sold 2,382 shares at $93.33 ($222K). Holdings down 10% to 20,679 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Christopher Peetz (CEO and Director) sold 7,098 shares at $93.33 ($662K). Holdings down 4% to 163,733 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Eric Bjerkholt (CFO) sold 1,421 shares at $93.33 ($133K). Holdings down 3% to 42,127 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 20, 2026 | Sale | Joanne Quan (Chief Medical Officer) sold 6,911 shares at $90.27 ($624K). Holdings down 38% to 11,305 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 15, 2026 | Planned (10b5-1) | Saira Ramasastry (Director) sold 2,000 shares at $90.99 ($182K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 16, 2026 |
| Dec 22, 2025 | Planned (10b5-1) | Saira Ramasastry (Director) sold 5,000 shares at $80.00 ($400K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 19, 2025 | Planned (10b5-1) | Michael G. Grey (Director) sold 50,000 shares at $78.00 ($3.9M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 18, 2025 | Planned (10b5-1) | Saira Ramasastry (Director) sold 2,000 shares at about $69.73 ($139K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 19, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Michael G. Grey (Director) sold 50,000 shares at $74.00 ($3.7M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 2, 2025 |
| Nov 21, 2025 | Planned (10b5-1) | Michael G. Grey (Director) sold 50,000 shares at $70.00 ($3.5M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Nov 25, 2025 |
59 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 4:03 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow MIRM in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.